Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C25H16F2N4O3 and a molecular weight of approximately 458.42 g/mol. It belongs to the class of aromatic anilides and features both fluorinated phenyl and pyrrolopyridine moieties. The compound has been studied as an experimental agent in drug discovery programs but does not have established clinical use or approved therapeutic indications. Computational studies suggest it may act as an inhibitor of viral proteins such as the nsp16/nsp10 complex involved in SARS-CoV‑2 RNA methylation, indicating potential antiviral activity; however, there are no confirmed mechanisms or clinical data supporting its efficacy or safety in humans[6]. Its primary use to date is for research purposes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide.